Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Feb;75(3):321-7.
doi: 10.1007/s40265-015-0356-3.

Blinatumomab: first global approval

Mark Sanford  1
Affiliations
Review

Blinatumomab: first global approval

Mark Sanford. Drugs. 2015 Feb.

Abstract

Blinatumomab (BLINCYTO™) is a novel, bispecific T-cell engaging antibody that binds cluster of differentiation (CD) 19 antigens on blast cells while also binding and activating the CD3/T cell receptor complex, causing cell lysis. The antibody is being developed by Amgen as a treatment for haematological cancers that originate from B cell lines. Blinatumomab was approved by the US FDA in December 2014 for the treatment of adults with Philadelphia chromosome (Ph)-negative relapsed/refractory B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). It is awaiting approval for this indication in the EU and is in phase III development in various countries. This article summarizes the milestones in the development of blinatumomab leading to its first approval for the treatment of Ph-negative BCP-ALL.

PubMed Disclaimer

References

    1. J Clin Oncol. 2014 Dec 20;32(36):4134-40 - PubMed
    1. J Clin Oncol. 2011 Jun 20;29(18):2493-8 - PubMed
    1. Blood Cancer J. 2014 Sep 05;4:244 - PubMed
    1. Drugs. 2011 Mar 5;71(4):415-42 - PubMed
    1. Leuk Res. 2009 Mar;33(3):465-73 - PubMed

MeSH terms

LinkOut - more resources